Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP

Clinical trial NCT04155411 · UNKNOWN

Trial details

NCT number: NCT04155411
Sponsor: Shenzhen Second People's Hospital
Status: UNKNOWN
Phase: Phase 4
Study type: INTERVENTIONAL

Dasatinib BCR-ABL Chronic Myeloid Leukemia

Start date: 2019-12-01
Primary completion: 2022-12-01
Enrollment: 65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.